Maximal Fat Oxidation and Fuel Use During Exercise

NCT04678713 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-15

No results posted yet for this study

Summary

Fat and carbohydrate are the two main energy stores available as fuel during exercise. It is well known that the exercise intensity and feeding status are the major factors determining the type of fuel used during exercise. During prolonged exercise at low to moderate exercise fat is the primary fuel being used and to improve performance studies has tried to understand strategies to maximize muscle glycogen storage and elevate fat oxidation during exercise. With this strategy they aim for preserving the limited muscle glycogen stores and thus improving endurance performance. In relation to this the maximal fat oxidation (MFO: The highest rate of fat oxidation across all exercise intensities) has been studied as increasing the fat oxidation could decrease the depletion of the glycogen stores. Further it has recently been shown that MFO is related to performance in endurance trained. However the MFO has been found to vary markedly between trained individuals matched on their activity level.

It has been suggested that the diet and subsequent substrate availability during exercise contributes independently to the variation in MFO. However, the measurements have never been evaluated in a trained group with similar aerobic capacity and training status. Therefore, the aim of the study is to investigate the effect of a short term fat rich or carbohydrate rich diet on MFO in well trained men with a high vs. a low MFO. The hypothesis is that 3 days of a fat-rich diet will increase MFO while 3 days of a Carbohydrate rich diet will decrease MFO in both individuals with a high MFO (HiMFO) and a low MFO (LoMFO). Furthermore, it is hypothesized that HiMFO will have a significantly higher MFO after both diets compared to LoMFO.

Lifestyle and physiological factors have been investigated to determine the variation of the MFO capacity. However, these factors can only explain 50% of the interindividual variability in MFO. Despite the critical role of fat oxidation during exercise, few studies have explored the differences in skeletal muscle characteristics between HiMFO and LoMFO. The second aim of the study is thereby to investigate if muscle characteristics can explain the variability in MFO within well-trained males. The hypothesis is that HiMFO will have more favorable muscle characteristics for fat oxidation compared to LoMFO including a higher oxidative capacity, intramuscular triacylglycerol concentration and a higher expression of key enzymes in lipid metabolism.

Conditions

Interventions

DIETARY_SUPPLEMENT

investigate the nutritional determinants of MFO in moderate to well-train individuals

The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.

OTHER

Investigate the physiological determinants of MFO in moderate to well-train individuals

Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.

Sponsors & Collaborators

  • Deakin University

    collaborator OTHER
  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Jørn Helge, Professor · Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-09-01
Completion
2021-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678713 on ClinicalTrials.gov